# 59417-101-10 · Lisdexamfetamine Dimesylate Capsule · Takeda Pharmaceuticals USA Inc. — FDA drug shortage duration tracker

For 59417-101-10 · Lisdexamfetamine Dimesylate Capsule · Takeda Pharmaceuticals USA Inc., package ndc is 59417-101-10; generic name is Lisdexamfetamine Dimesylate Capsule; manufacturer is Takeda Pharmaceuticals USA Inc; status is Current; availability now is Available, recorded from its source on 2026-09-01; source re-checked 2026-09-16.

- **Package NDC:** 59417-101-10 _(verified: appears in the quote below)_
- **Generic name:** Lisdexamfetamine Dimesylate Capsule _(verified: appears in the quote below)_
- **Manufacturer:** Takeda Pharmaceuticals USA Inc. _(verified: appears in its own passage below)_
- **Status:** Current _(verified: appears in its own passage below)_
- **Availability now:** Available _(verified: appears in the quote below)_
- **Initial posting date:** 07/14/2023 _(verified: appears in the quote below)_
- **Last update date:** 06/23/2026 _(verified: appears in its own passage below)_
- **Days in shortage:** 1145 _(our reading, not quoted from the source)_
- **Dosage form:** Capsule _(verified: appears in its own passage below)_
- **Therapeutic category:** Psychiatry _(verified: appears in its own passage below)_

## What the source says

> "initial_posting_date": "07/14/2023", "package_ndc": "59417-101-10", "generic_name": "Lisdexamfetamine Dimesylate Capsule", "contact_info": "877-TAKEDA-7 (1-877-825-3327)", "availability": "Available"

## Where each value comes from

This source states these in separate places, so each value is shown with the passage that states it.

### Manufacturer

> "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current"

### Status

> "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current"

### Last update date

> "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current"

### Dosage form

> "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current"

### Therapeutic category

> "update_date": "06/23/2026", "therapeutic_category": [ "Psychiatry" ], "dosage_form": "Capsule", "presentation": "Vyvanse, Capsule, 10 mg (NDC 59417-101-10)", "company_name": "Takeda Pharmaceuticals USA Inc.", "status": "Current"

## Source

- https://api.fda.gov/drug/shortages.json?search=company_name%3A%22Takeda%20Pharmaceuticals%20USA%20Inc.%22+AND+generic_name%3A%22Lisdexamfetamine%20Dimesylate%20Capsule%22+AND+status%3A%22Current%22&limit=1000

Last verified: 2026-09-16. Review by: 2026-09-19.
Part of [FDA drug shortage duration tracker](https://referencesource.org/drug-shortage-duration-tracker/).